BridgeMD
New treatment option for Acute Myocardial Infarction
Official title Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction
ClinicalTrials.gov ID: NCT06364150
What this study is testing
What is Autologous Peripheral Blood Stem Cell injection?
Autologous Peripheral Blood Stem Cell injection is an investigational medicine, being studied as a potential treatment for acute myocardial infarction.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study will evaluate the efficacy and safety of "Therapeutic Use of Autologous-Primed Autologous Peripheral Blood Stem Cell Treatment for Myocardial Regeneration in Acute Myocardial Infarction".
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 to 80
You may be able to join if
- 1\. Male and female aged ≥19 years and ≤ 80 years
- 2\. A clinical diagnosis of acute myocardial infarction within 4 weeks from randomization
- 3\. Successful percutaneous coronary intervention to the target lesion (TIMI flow grade 3 and residual stenosis \<30% at the target lesion) with a...
- 4\. Agreement to give written informed consent.
You likely can't join if
- Patients with uncontrolled heart failure (Killip class ≥ grade 2, or left ventricular ejection fraction \<20%)
- Patients with uncontrolled chest pain due to ischemia
- Patients with uncontrolled arrythmia
- Active malignancy, or incompletely treated malignancy
- Active infectious disease
- Uncontrolled hematologic disease, including coagulopathy or bleeding diathesis
See the full eligibility criteria
- 1\. Male and female aged ≥19 years and ≤ 80 years
- 2\. A clinical diagnosis of acute myocardial infarction within 4 weeks from randomization
- 3\. Successful percutaneous coronary intervention to the target lesion (TIMI flow grade 3 and residual stenosis \<30% at the target lesion) with a drug-eluting stent and/or drug-eluting balloon
- 4\. Agreement to give written informed consent.
- Patients with uncontrolled heart failure (Killip class ≥ grade 2, or left ventricular ejection fraction \<20%)
- Patients with uncontrolled chest pain due to ischemia
- Patients with uncontrolled arrythmia
- Active malignancy, or incompletely treated malignancy
- Active infectious disease
- Uncontrolled hematologic disease, including coagulopathy or bleeding diathesis
- Presence of non-cardiac comorbidity with life expectancy ≤1 year from randomization
- Females with childbearing potential or breast-feeding
- Refusal to give written informed consent
- Other conditions that may result in protocol non-compliance by the committees
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.